1-3 of 3
Charles RM Hay
Close
Sort by
Journal Articles

First-in-Human Dose-Finding Study of AAVhu37 Vector-Based Gene Therapy: BAY 2599023 Has Stable and Sustained Expression of FVIII over 2 Years

Steven W Pipe, John P Sheehan, Michiel Coppens, Hermann Eichler, Camila Linardi, Sara Wiegmann, Charles RM Hay, Toshko Lissitchkov
Journal: Blood
Blood (2021) 138 (Supplement 1): 3971.
https://doi.org/10.1182/blood-2021-148661
Published: 2021
Journal Articles

Prospective Observation on the Use of Von Willebrand Factor (VWF) Concentrates in a Large Cohort of Type 3 Von Willebrand Disease (VWD): Interim (18-months) Analyses on 149 Cases Enrolled into the 3Winters-Ips Project

Augusto B Federici, MD, Zahra Badiee, Mohammad-Reza Baghaipour, Giancarlo Castaman, Peyman Eshghi, MD, Jenny Goudemand, MD PhD, Charles RM Hay, MD, Hamid Hoorfar, MD, Mehran Karimi, MD, Bijan Keikhaei, Riitta Lassila, MD PR, Frank Leebeek, Maria Fernanda Lopez Fernandez, Renato Marino, Ian Peake, PhD, Rafael Parra Lòpez, Flora Peyvandi, MD PhD, Cristina Santoro, MD PhD, Simona Maria Siboni, Alberto Tosetto, Marc Trossaert, Jeroen C.J. Eikenboom, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2464.
https://doi.org/10.1182/blood-2018-99-112447
Published: 2018
Journal Articles

101HEMB01 Is a Phase 1/2 Open-Label, Single Ascending Dose-Finding Trial of DTX101 (AAVrh10FIX) in Patients with Moderate/Severe Hemophilia B That Demonstrated Meaningful but Transient Expression of Human Factor IX (hFIX)

Steven Pipe, MD, Kimo Stine, MD, Anita Rajasekhar, MD, Tamara Everington, MD, Allen Poma, MD, Eric Crombez, MD, Charles RM Hay, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3331.
https://doi.org/10.1182/blood.V130.Suppl_1.3331.3331
Published: 2017